InMed Pharmaceuticals Net Income
| INM Stock | USD 0.88 0.01 1.12% |
As of the 13th of February 2026, InMed Pharmaceuticals retains the risk adjusted performance of (0.09), and Market Risk Adjusted Performance of (0.45). InMed Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out InMed Pharmaceuticals variance and potential upside to decide if InMed Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 0.88 per share. Given that InMed Pharmaceuticals is a hitting penny stock territory we urge to closely look at its jensen alpha.
InMed Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.1247 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.3 M | -7 M | |
| Net Loss | -7.3 M | -7.7 M | |
| Net Loss | -7.2 M | -7.5 M | |
| Net Loss | (372.20) | (390.81) | |
| Net Income Per E B T | 0.90 | 0.80 |
InMed | Net Income | Build AI portfolio with InMed Stock |
Evaluating InMed Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into InMed Pharmaceuticals's fundamental strength.
Latest InMed Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of InMed Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in InMed Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of InMed Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is InMed Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in InMed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.16 M) | 10 Years Trend |
|
Net Income |
| Timeline |
InMed Net Income Regression Statistics
| Arithmetic Mean | (6,435,865) | |
| Coefficient Of Variation | (74.22) | |
| Mean Deviation | 3,606,836 | |
| Median | (6,978,624) | |
| Standard Deviation | 4,776,577 | |
| Sample Variance | 22.8T | |
| Range | 18.6M | |
| R-Value | (0.63) | |
| Mean Square Error | 14.8T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | (593,080) | |
| Total Sum of Squares | 365.1T |
InMed Net Income History
Other Fundumenentals of InMed Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
InMed Pharmaceuticals Net Income component correlations
InMed Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for InMed Pharmaceuticals is extremely important. It helps to project a fair market value of InMed Stock properly, considering its historical fundamentals such as Net Income. Since InMed Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of InMed Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of InMed Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could InMed diversify its offerings? Factors like these will boost the valuation of InMed Pharmaceuticals. Market participants price InMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every InMed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.09) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
Understanding InMed Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects InMed's accounting equity. The concept of intrinsic value - what InMed Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push InMed Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, InMed Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
InMed Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to InMed Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of InMed Pharmaceuticals.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in InMed Pharmaceuticals on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding InMed Pharmaceuticals or generate 0.0% return on investment in InMed Pharmaceuticals over 90 days. InMed Pharmaceuticals is related to or competes with Biodexa Pharmaceticals, Genprex, Biovie, Galmed Pharmaceuticals, GRI Bio, CNS Pharmaceuticals, and Jaguar Animal. InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products More
InMed Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure InMed Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess InMed Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 30.84 | |||
| Value At Risk | (10.10) | |||
| Potential Upside | 7.48 |
InMed Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for InMed Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as InMed Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use InMed Pharmaceuticals historical prices to predict the future InMed Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.84) | |||
| Total Risk Alpha | (1.23) | |||
| Treynor Ratio | (0.46) |
InMed Pharmaceuticals February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.45) | |||
| Mean Deviation | 4.45 | |||
| Coefficient Of Variation | (811.86) | |||
| Standard Deviation | 5.81 | |||
| Variance | 33.7 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.84) | |||
| Total Risk Alpha | (1.23) | |||
| Treynor Ratio | (0.46) | |||
| Maximum Drawdown | 30.84 | |||
| Value At Risk | (10.10) | |||
| Potential Upside | 7.48 | |||
| Skewness | (0.27) | |||
| Kurtosis | 0.5743 |
InMed Pharmaceuticals Backtested Returns
InMed Pharmaceuticals holds Efficiency (Sharpe) Ratio of -0.15, which attests that the entity had a -0.15 % return per unit of volatility over the last 3 months. InMed Pharmaceuticals exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out InMed Pharmaceuticals' market risk adjusted performance of (0.45), and Risk Adjusted Performance of (0.09) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.58, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, InMed Pharmaceuticals will likely underperform. At this point, InMed Pharmaceuticals has a negative expected return of -0.85%. Please make sure to check out InMed Pharmaceuticals' information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if InMed Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.24 |
Weak predictability
InMed Pharmaceuticals has weak predictability. Overlapping area represents the amount of predictability between InMed Pharmaceuticals time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of InMed Pharmaceuticals price movement. The serial correlation of 0.24 indicates that over 24.0% of current InMed Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.24 | |
| Spearman Rank Test | 0.39 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
InMed Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, InMed Pharmaceuticals reported net income of (8.16 Million). This is 102.39% lower than that of the Biotechnology sector and 111.65% lower than that of the Health Care industry. The net income for all United States stocks is 101.43% higher than that of the company.
InMed Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InMed Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of InMed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing InMed Pharmaceuticals by comparing valuation metrics of similar companies.InMed Pharmaceuticals is currently under evaluation in net income category among its peers.
InMed Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in InMed Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of InMed Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing InMed Pharmaceuticals' value.| Shares | Ubs Group Ag | 2025-06-30 | 7.8 K | Tower Research Capital Llc | 2025-06-30 | 400 | Sbi Securities Co Ltd | 2025-06-30 | 300 | Banque Cantonale Vaudoise | 2025-06-30 | 6.0 | Allsquare Wealth Management Llc | 2025-06-30 | 1.0 | Federation Des Caisses Desjardins Du Quebec | 2025-06-30 | 1.0 | Advisorshares Investments, Llc | 2025-03-31 | 0.0 |
InMed Fundamentals
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (1.71) % | ||||
| Operating Margin | (1.57) % | ||||
| Current Valuation | (5.87 M) | ||||
| Shares Outstanding | 2.8 M | ||||
| Shares Owned By Insiders | 0.14 % | ||||
| Shares Owned By Institutions | 15.48 % | ||||
| Number Of Shares Shorted | 165.21 K | ||||
| Price To Book | 0.24 X | ||||
| Price To Sales | 0.58 X | ||||
| Revenue | 4.94 M | ||||
| Gross Profit | 1.62 M | ||||
| EBITDA | (7.26 M) | ||||
| Net Income | (8.16 M) | ||||
| Cash And Equivalents | 9.35 M | ||||
| Cash Per Share | 9.98 X | ||||
| Total Debt | 741.26 K | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 3.52 X | ||||
| Book Value Per Share | 2.93 X | ||||
| Cash Flow From Operations | (7.77 M) | ||||
| Short Ratio | 1.91 X | ||||
| Earnings Per Share | (6.09) X | ||||
| Target Price | 20.0 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.4 | ||||
| Market Capitalization | 2.78 M | ||||
| Total Asset | 15.58 M | ||||
| Retained Earnings | (117.24 M) | ||||
| Working Capital | 11.03 M | ||||
| Net Asset | 15.58 M |
About InMed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze InMed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InMed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InMed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Will Biotechnology sector continue expanding? Could InMed diversify its offerings? Factors like these will boost the valuation of InMed Pharmaceuticals. Market participants price InMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every InMed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.09) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
Understanding InMed Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects InMed's accounting equity. The concept of intrinsic value - what InMed Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push InMed Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, InMed Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.